Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial

<p>Abstract</p> <p>Background</p> <p>Suicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors o...

Full description

Bibliographic Details
Main Authors: Giovannini Caterina, Zobel Astrid, Strohmaier Jana, Jorgensen Lisbeth, Szczepankiewicz Aleksandra, Placentino Anna, Souery Daniel, Maier Wolfgang, Hauser Joanna, Henigsberg Neven, Mors Ole, Rietschel Marcella, Marusic Andrej, Uher Rudolf, Perroud Nader, Elkin Amanda, Gunasinghe Cerisse, Gray Joanna, Campbell Desmond, Gupta Bhanu, Farmer Anne E, McGuffin Peter, Aitchison Katherine J
Format: Article
Language:English
Published: BMC 2009-10-01
Series:BMC Medicine
Online Access:http://www.biomedcentral.com/1741-7015/7/60
id doaj-f66621292ae74a88b19c2f9e43bf0d56
record_format Article
spelling doaj-f66621292ae74a88b19c2f9e43bf0d562020-11-24T21:54:20ZengBMCBMC Medicine1741-70152009-10-01716010.1186/1741-7015-7-60Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trialGiovannini CaterinaZobel AstridStrohmaier JanaJorgensen LisbethSzczepankiewicz AleksandraPlacentino AnnaSouery DanielMaier WolfgangHauser JoannaHenigsberg NevenMors OleRietschel MarcellaMarusic AndrejUher RudolfPerroud NaderElkin AmandaGunasinghe CerisseGray JoannaCampbell DesmondGupta BhanuFarmer Anne EMcGuffin PeterAitchison Katherine J<p>Abstract</p> <p>Background</p> <p>Suicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors of emergence and worsening of suicidal ideation during tricyclic antidepressant and serotonin reuptake inhibitor treatment.</p> <p>Methods</p> <p>In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal ideation at baseline.</p> <p>Results</p> <p>Suicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram, respectively. Retirement and history of suicide attempts predicted TWOSI.</p> <p>Conclusion</p> <p>Increases in suicidal ideation were associated with depression severity and decreased during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation beyond the initial weeks of antidepressant treatment.</p> <p>Trial registration</p> <p>EudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).</p> http://www.biomedcentral.com/1741-7015/7/60
collection DOAJ
language English
format Article
sources DOAJ
author Giovannini Caterina
Zobel Astrid
Strohmaier Jana
Jorgensen Lisbeth
Szczepankiewicz Aleksandra
Placentino Anna
Souery Daniel
Maier Wolfgang
Hauser Joanna
Henigsberg Neven
Mors Ole
Rietschel Marcella
Marusic Andrej
Uher Rudolf
Perroud Nader
Elkin Amanda
Gunasinghe Cerisse
Gray Joanna
Campbell Desmond
Gupta Bhanu
Farmer Anne E
McGuffin Peter
Aitchison Katherine J
spellingShingle Giovannini Caterina
Zobel Astrid
Strohmaier Jana
Jorgensen Lisbeth
Szczepankiewicz Aleksandra
Placentino Anna
Souery Daniel
Maier Wolfgang
Hauser Joanna
Henigsberg Neven
Mors Ole
Rietschel Marcella
Marusic Andrej
Uher Rudolf
Perroud Nader
Elkin Amanda
Gunasinghe Cerisse
Gray Joanna
Campbell Desmond
Gupta Bhanu
Farmer Anne E
McGuffin Peter
Aitchison Katherine J
Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
BMC Medicine
author_facet Giovannini Caterina
Zobel Astrid
Strohmaier Jana
Jorgensen Lisbeth
Szczepankiewicz Aleksandra
Placentino Anna
Souery Daniel
Maier Wolfgang
Hauser Joanna
Henigsberg Neven
Mors Ole
Rietschel Marcella
Marusic Andrej
Uher Rudolf
Perroud Nader
Elkin Amanda
Gunasinghe Cerisse
Gray Joanna
Campbell Desmond
Gupta Bhanu
Farmer Anne E
McGuffin Peter
Aitchison Katherine J
author_sort Giovannini Caterina
title Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
title_short Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
title_full Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
title_fullStr Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
title_full_unstemmed Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial
title_sort suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (gendep): a clinical trial
publisher BMC
series BMC Medicine
issn 1741-7015
publishDate 2009-10-01
description <p>Abstract</p> <p>Background</p> <p>Suicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors of emergence and worsening of suicidal ideation during tricyclic antidepressant and serotonin reuptake inhibitor treatment.</p> <p>Methods</p> <p>In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal ideation at baseline.</p> <p>Results</p> <p>Suicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram, respectively. Retirement and history of suicide attempts predicted TWOSI.</p> <p>Conclusion</p> <p>Increases in suicidal ideation were associated with depression severity and decreased during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation beyond the initial weeks of antidepressant treatment.</p> <p>Trial registration</p> <p>EudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).</p>
url http://www.biomedcentral.com/1741-7015/7/60
work_keys_str_mv AT giovanninicaterina suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT zobelastrid suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT strohmaierjana suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT jorgensenlisbeth suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT szczepankiewiczaleksandra suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT placentinoanna suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT souerydaniel suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT maierwolfgang suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT hauserjoanna suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT henigsbergneven suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT morsole suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT rietschelmarcella suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT marusicandrej suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT uherrudolf suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT perroudnader suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT elkinamanda suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT gunasinghecerisse suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT grayjoanna suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT campbelldesmond suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT guptabhanu suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT farmerannee suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT mcguffinpeter suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
AT aitchisonkatherinej suicidalideationduringtreatmentofdepressionwithescitalopramandnortriptylineingenomebasedtherapeuticdrugsfordepressiongendepaclinicaltrial
_version_ 1725867451886862336